Cardiome Pharma Corp is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at wxx.xxxxxxxx.xxx.
Cardiome Pharma Corp. (“Cardiome”), for itself and its successors in interest and assigns, hereby irrevocably and unconditionally guarantees the full and faithful payment and performance by Licensee of all of the payment and performance obligations of Licensee set forth in this Agreement or the Ancillary Agreements in strict accordance with the terms hereof. Pursuant to the foregoing, Cardiome is obligated to make each payment, and to perform each other obligation, contemplated by this Agreement or the Ancillary Agreements on the date when due, without notice to or demand upon Licensee or Cardiome. In addition, Cardiome does hereby waive notice of acceptance of this guaranty, notice of protest or compliance with the terms and provisions of this Agreement and the Ancillary Agreements and notice of non-performance or non-observance hereof. This guaranty, and payment and performance by Cardiome hereunder and thereunder, is in no way conditioned upon any requirement that Allergan first attempt to collect or enforce any obligation from or against Licensee, or upon any other event, action or inaction of any nature whatsoever.
Cardiome Pharma Corp s/ Xxxxxxxx M.N. Xxxxx /s/ Xxxxxxx Xxxxxx Signature Signature Name: Xxxxxxxx M.N. Xxxxx Name: Xxxxxxx Xxxxxx Title: President and CEO Title: CEO /s/ Xxxxxxxx Xxxxxxxxx Signature Name: Xxxxxxxx Xxxxxxxxx Title: CFO Correvio International Sárl /s/ Xxxxx X. XxXxxxxxx Signature Name: Xxxxx X. XxXxxxxxx Title: Director /s/ Xxxxxxxx Xxxxxxxxx Signature Name: Xxxxxxxx Xxxxxxxxx Title: Director [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Schedule 1.6(a) Cardiome Anti-Corruption Policy CARDIOME PHARMA CORP. CORREVIO INTERNATIONAL Sàrl CODE OF BUSINESS CONDUCT AND ETHICS
Cardiome Pharma Corp is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.
Cardiome Pharma Corp is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at xxx.xxxxxxxx.xxx. Merck Forward-Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended December 31, 2008, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference. Cardiome Forward-Looking Statement Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market...
Cardiome Pharma Corp. (XXX.XX) Enters Commercialization Agreement With Aspen For BRINAVESS® In South Africa VANCOUVER, Nov. 17, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that an affiliate of the company has entered into an agreement with Pharmacare Limited, which trades as Aspen Pharmacare and is a part of the Aspen Group, to sell and distribute BRINAVESS® (vernakalant intravenous) exclusively in South Africa. Under the terms of the agreement, Aspen has agreed to specific annual commercial goals for BRINAVESS. Financial details of the agreement have not been disclosed. "We are pleased to expand our commercial agreement with Aspen to now include BRINAVESS in South Africa," said Xxxxx Xxxxx, Xxxxxxxx's Chief Commercial Officer. "Aspen has proven to be a valuable partner to Cardiome through their commercialization efforts behind AGGRASTAT®. This will be the first country in Africa where XXXXXXXXX will be launched and we remain committed to making this drug available to all our customers worldwide." "It is exciting for us to expand our portfolio to now include BRINAVESS alongside Xxxxxxxx's AGGRASTAT," said Xxxx Xxxxxx, CEO at Aspen Pharmacare, South Africa. "We are looking forward to making it available to all of our hospital customers throughout the country." In 2014, the South African pharmaceutical market was estimated to be valued at ZAR 30.6.1 References: Espicom. The Pharmaceutical Market: South Africa, Oct 2014 About Cardiome Pharma Corp. Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS® (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome. Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at xxx.xxxxxxxx.xxx. About Aspen Aspen is a global supplier of branded and generic pharmaceutical products as well as infant milk nutritionals and consumer healthcare products in selected territories. Aspen is the largest pharmaceutical company listed on the South African stock exchange, the JSE...
